Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for chronic migraine in a US tertiary headache center

被引：0
|
作者：
Cohen, Fred [1 ]
Yuan, Hsiangkuo [1 ]
Dent, Kathryn [1 ]
Beucherie, Matthew [1 ]
Connolly, William [1 ]
Driessen, Maurice [2 ]
Krasenbaum, Lynda J. [3 ]
Carr, Karen [4 ]
Hopkins, Mary [1 ]
Marmura, Michael [1 ]
机构：
[1] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA USA
[2] Teva Netherlands BV, Global Med Affairs, Amsterdam, Netherlands
[3] Teva Branded Pharmaceut Prod R&D Inc, Global Med Affiars, W Chester, PA USA
[4] US Med Affairs, Teva Pharmaceut, Parsippany, NJ USA
来源：
CEPHALALGIA | 2022年 / 42卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS22-LBA
引用
收藏
页码：127 / 128
页数：2
相关论文
共 50 条
  • [1] Real-world effectiveness of fremanezumab in patients with refractory migraine from a US tertiary headache center who switched from erenumab
    Yuan, H.
    Hopkins, M.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    Marmura, M. J.
    HEADACHE, 2022, 62 : 156 - 157
  • [2] Real-world Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab in the US
    Cohen, Joshua M.
    Thompson, Stephen
    Patterson-Lomba, Oscar
    Driessen, Maurice
    Seminerio, Michael
    Carr, Karen
    Mu, Fan
    NEUROLOGY, 2021, 96 (15)
  • [3] US Real-world Effectiveness of Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in Adult Patients With Migraine
    Cohen, Joshua M.
    Thompson, Stephen
    Ayyagari, Rajeev
    Driessen, Maurice
    Seminerio, Michael
    Carr, Karen
    Yim, Erica
    NEUROLOGY, 2021, 96 (15)
  • [4] Real-world effectiveness after initiating fremanezumab treatment of 165 migraine patients in a regional headache center in Japan
    Kikui, Shoji
    Danno, Daisuke
    Miyahara, Junichi
    Sugyama, Hanako
    Ota, Kuniko
    Murakata, Kenji
    Kashiwaya, Yoshihiro
    Takeshima, Takao
    CEPHALALGIA, 2023, 43 (1supp) : 236 - 236
  • [5] REDUCTIONS IN MIGRAINE AND HEADACHE DAYS WITH QUARTERLY AND MONTHLY FREMANEZUMAB IN ADULT PATIENTS WITH MIGRAINE IN A US REAL-WORLD SETTING
    Cohen, J.
    Thompson, S.
    Ayyagari, R.
    Driessen, M.
    Seminerio, M.
    Carr, K.
    Yim, E.
    VALUE IN HEALTH, 2022, 25 (01) : S36 - S36
  • [6] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Driessen, Maurice T.
    Cohen, Joshua M.
    Thompson, Stephen F.
    Patterson-Lomba, Oscar
    Seminerio, Michael J.
    Carr, Karen
    Totev, Todor, I
    Sun, Rochelle
    Yim, Erica
    Mu, Fan
    Ayyagari, Rajeev
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [7] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Maurice T. Driessen
    Joshua M. Cohen
    Stephen F. Thompson
    Oscar Patterson-Lomba
    Michael J. Seminerio
    Karen Carr
    Todor I. Totev
    Rochelle Sun
    Erica Yim
    Fan Mu
    Rajeev Ayyagari
    The Journal of Headache and Pain, 2022, 23
  • [8] Real-world Reductions in Migraine and Headache Days for Patients With Migraine Initiating Fremanezumab in Germany
    Heinze, A.
    Totev, T.
    Krasenbaum, L.
    Terasawa, E.
    Akcicek, H.
    Hipp, J.
    Sun, R.
    Yim, E.
    Driessen, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 419 - 419
  • [9] Real-world economic impact of onabotulinumtoxina in patients with chronic migraine
    JF Rothrock
    LM Bloudek
    TT Houle
    D Andress-Rothrock
    C Hanlon
    SF Varon
    The Journal of Headache and Pain, 2013, 14
  • [10] Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
    Rothrock, John F.
    Bloudek, Lisa M.
    Houle, Timothy T.
    Andress-Rothrock, Diane
    Varon, Sepideh F.
    HEADACHE, 2014, 54 (10): : 1565 - 1573
12345